H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Synthorx Inc (THOR) today and set a price target of $30. The company’s shares closed yesterday at $17.90.
Chattopadhyay observed:
“Our 12-month, $30 price target on shares of Synthorx is based on a 12-year DCF-based, sum-of-the-parts analysis. Our DCF is driven by: beta of 1.5, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.2%, and tax rate of 15% beginning in FY 2029. We assign a 9% POS for THOR-707, which we anticipate could be developed in NSCLC, RCC, melanoma, and urothelial cancer. These indications together represent about 95% of our target with NSCLC being the biggest driver of valuation, elaborated upon subsequently.”
According to TipRanks.com, Chattopadhyay is a 3-star analyst with an average return of 2.5% and a 45.8% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Voyager Therapeutics Inc, and Mersana Therapeutics Inc.
Synthorx Inc has an analyst consensus of Moderate Buy, with a price target consensus of $25.50.
See today’s analyst top recommended stocks >>
Based on Synthorx Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $28.16 million. In comparison, last year the company had a GAAP net loss of $2.19 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Synthorx, Inc. is a biopharmaceutical company, which focuses on prolonging and improving lives of cancer and autoimmune disorder patients. Its product pipeline is comprised of THOR-707, IL-2 Synthorin, IL-10 Synthorin, and IL-15 Synthorin. The company was founded by Floyd E. Romesberg and Court R. Turner in 2014 and is headquartered in La Jolla, CA.
